

Index

A

Acute lymphoblastic leukemia
(ALL), 265, 266
Acute myeloid leukemia (AML), 265, 266
 α -globin, 20, 31, 32
Autoimmune diseases, 254, 267, 269

B

β -globin, 7, 20–27, 29–33, 63, 64, 233
BMP2. *See* Bone morphogenic protein 2 (*BMP2*)
Bone mineral density (BMD), 42, 56, 68
Bone morphogenic protein 2 (*BMP2*), 76, 81, 85–86
Brachydactyly, 81, 82, 84–86, 237
Breast cancer, 183, 184, 205–206, 263, 264, 267

C

Campomelic dysplasia, 112, 125–128
CCCTC-binding factor (CTCF), 6, 9, 231–234
ChIP. *See* Chromatin immunoprecipitation (ChIP)
Chondrogenesis, 126, 130
Chromatin, 5–8, 22, 109, 112, 113, 128, 130, 157, 199, 203, 205, 206, 212, 218, 223–227, 229, 231, 233, 236, 241, 254–256, 268, 269
Chromatin immunoprecipitation (ChIP), 2, 6, 8, 9, 48, 75, 113, 114, 144, 155, 179, 199, 203, 206, 230, 271
Cleft
lip, 95–116
palate, 95–116, 124, 130, 131

Cochlea, 138–140, 142, 143, 148, 152–155, 158
Cohesion, 217–243
Colorectal cancer, 203–208, 242, 264
Conserved non-coding element (CNEs), 127–129, 132
Cornelia de Lange syndrome (CdLS), 5, 222, 224, 229, 235–240
Cranial neural crest, 99, 124, 125, 128, 130
Craniofacial, 96, 100, 103, 106, 110, 112–114, 116, 123, 125, 126, 129–132, 235, 241
CTCF. *See* CCCTC-binding factor (CTCF)

D

Deafness, 56, 58, 137–158
DFNA, 141–153
DFNB, 145, 153–156
DFNX, 143–146
DNA double-stranded-breaks (DSB), 209, 218, 224, 228–229, 236
DNA hypermethylation, 259–261, 265
DNA methylation, 6, 9, 254–255, 259–265, 268–269, 271, 272
DNaseI hypersensitive sites, 103, 105

E

ECR5 enhancer, 63–66
EIF3H. *See* Eukaryotic translation initiation factor 3 subunit H (EIF3H)
Enhancer, 2, 20, 62, 73–88, 98, 127, 140, 177, 196, 222, 257
Enteric nervous system, 170–174, 176, 178, 179, 181–184

- Epigenetics, 253–273
 ε-globin, 20, 23
 Estrogen Receptor, 44
 Estrogen-related receptor (*ESRRB*), 154–156
ETS, 210–211
 Eukaryotic translation initiation factor 3
 subunit H (EIF3H), 207–208
 Eyes absent drosophila homolog 4 (*EYA4*),
 146–148, 151
- F**
 Fibroblast growth factor receptor 2
 (*FGFR2*), 205–206
 Forkhead box E1 (*FOXE1*), 102, 110–112, 201
- G**
 γ-globin, 20–30, 32
 Grainyhead-like 2 (*GRHL2*), 151–153
- H**
 HATs. *See* Histone acetyltransferases (HATs)
 HDMs. *See* Histone demethylases (HDMs)
 Hematologic cancer, 209–210
 Hemoglobin, 19–33
 Hemoglobin switching, 7, 20–22, 24, 26, 33
 Hepatocyte growth factor (*HGF*), 153–154
 Hereditary persistence of fetal hemoglobin
 (HPFH), 25, 28, 33
HGF. *See* Hepatocyte growth factor (*HGF*)
 High bone mass (HBM), 43, 56, 66–68
 Hirschsprung, 169–185
 Histone acetyltransferases (HATs), 6, 257,
 265, 266
 Histone deacetylases (HDACs), 255–257, 272
 Histone demethylases (HDMs), 257, 265
 Histone methyltransferases (HMTs), 255–257,
 265, 266
- I**
 Immunoglobulin (Ig), 209–210
 Insulator, 2, 3, 5–7, 9, 11, 13, 231–233
 Interferon regulatory factor 6 (*IRF6*),
 101–111, 113–116
- L**
 Limb, 4, 73–88, 96, 98, 107–110, 126, 171,
 197, 204, 222, 235–237, 239, 240
 Locus control region (LCR), 7, 20, 22,
 26, 27, 209
- M**
 Malignancies, 242–243, 259, 261, 263, 265
MCS9.7, 98, 102, 103, 105–110, 113, 115, 117
 MeCP2. *See* Methyl-CpG binding protein 2
 (MeCP2)
 Meiosis, 103, 217, 219, 223, 236
 Methyl-CpG binding protein 2 (MeCP2),
 270–272
 MicroRNAs (miRNAs), 140, 148–151, 158,
 258, 265–267
 Microsminoprotein beta (*MSMB*), 198–200
MIR96, 148–151
 MiRNAs. *See* MicroRNAs (miRNAs)
 Mitosis, 217, 219, 223, 232, 236
MSMB. *See* Microsminoprotein
 beta (*MSMB*)
MYC. *See* Proto-oncogene v-myc
 myelocytomatosis viral oncogene
 homolog (*MYC*)
- N**
 Neural crest (NC), 99, 124–126,
 128, 130, 170, 171, 174,
 175, 179, 180, 183
 Neuregulin1 (*NRG1*), 180
 Nipped-B homolog (NIPBL), 5, 221, 222, 224,
 227, 229, 235, 238–241
NRG1. *See* Neuregulin1 (*NRG1*)
 Nucleosome positioning, 2
- O**
 Osteopetrosis, 56
- P**
PDGFC. *See* Platelet-derived growth factor C
 (*PDGFC*)
 Pierre Robin sequence, 112, 123–125
 Platelet-derived growth factor C (*PDGFC*),
 102, 110–112
 Polydactyly, 78–80, 86
 POU class 3 homeobox 4 (*POU3F4*),
 143–146, 151
 POU class 4 homeobox 3 (*POU4F3*),
 141–143, 150, 151
 Promoter, 2, 22, 44, 63, 75, 102, 128, 140,
 174, 196, 222, 255
 Prostate cancer, 198–200, 203–205,
 210–211
 Proto-oncogene v-myc myelocytomatosis viral
 oncogene homolog
 (*MYC*), 202–205

Q

8q24, 101, 202–205

R

cis-Regulatory element, 26, 74, 75, 83, 84, 86–88, 128, 196, 198, 199, 201–212
 Ret proto-oncogene (*RET*), 169–185
 Rett syndrome (RTT), 270–272
 Roberts syndrome (RBS), 235, 236, 240

S

SATB homeobox 2 (*SATB2*), 102, 112
 Sclerosteosis, 56–62, 66–69
 Sclerostin (SOST), 42, 56, 59–69
SHH. *See* Sonic hedgehog (*SHH*)
 Sickle cell disease (SCD), 23, 29–30
 Silencer, 2, 3, 5, 7, 9, 11–13, 23, 199, 201, 211, 231
 SMAD family member 7 (*SMAD7*), 206–207
SMC3, 219–221, 223–225, 227–229, 238–240, 242
SMC1A, 219, 220, 223, 229, 238–240, 242
 Sonic hedgehog (*SHH*), 4, 76–81, 84, 88
 SOST. *See* Sclerostin (SOST)
 SRY-box containing gene9 (*SOX9*), 12, 82, 86, 112–114, 123–132
 SRY-box containing gene10 (*SOX10*), 174, 179, 181, 182, 185
 Systemic lupus erythematosus (SLE), 267–270

T

T-box 22 (*TBX22*), 102, 110–112
 Thalassemia, 23, 29–33, 218

Thalassemia/mental retardation syndrome
 X-linked (*ATRX*), 218, 241

Thyroid cancer, 173, 201

TMPRSS2. *See* Transmembrane protease serine 2 (*TMPRSS2*)

TP63. *See* Tumor protein p63 (*TP63*)

Transcriptional regulation, 50, 65, 182, 184, 202

Transcription factors, 2–5, 7, 22, 24–26, 28, 44, 45, 47–49, 64–66, 68, 77, 87, 101–103, 105, 106, 108, 110–112, 114, 139–142, 144–147, 151–154, 156–158, 174, 179, 180, 182, 199, 201, 202, 204–206, 210–211, 235, 257, 262, 263, 265, 272

Transmembrane protease serine 2 (*TMPRSS2*), 210–211

Tumor protein p63 (*TP63*), 88, 101–103, 105, 108–109, 114

Type 1 collagen, 44–48

V

Van Buchem
 deletion, 61–62
 disease, 55–69

Vitamin D receptor (VDR), 48–50

W

Warsaw breakage syndrome, 241

Z

Zone of polarizing activity (ZPA), 76–79, 84

ZPA regulatory sequence (ZRS), 78–84, 86, 88